Skip to main content

Table 4 Percentage of resistance in Proteus spp. by antimicrobial and country in 2012-2013

From: European multicenter study on antimicrobial resistance in bacteria isolated from companion animal urinary tract infections

Countrya AMC 3GC FLU CN SXT Combined resistance
n % R (95 % CI)b
[Stat. Dif.]c
n % R (95 % CI)b
[Stat. Dif.]c
n % R (95 % CI)b
[Stat. Dif.]c
n % R (95 % CI)b
[Stat. Dif.]c
n % R (95 % CI)b
[Stat. Dif.]c
n % MDR (95 % CI)b
[Stat. Dif.]c
% FullS (95 % CI)b
[Stat. Dif.]c
AT 29 10.34 (0.00–21.43)
[a, b, c]
29 0
[a, b]
29 17.24 (3.49–30.99)
[a, b, c]
29 6.90 (0.00–16.12)
[a, b]
29 37.93 (20.27–55.59)
[a, b]
29 6.90 (0.00–16.12)
[a]
55.17 (37.07–73.27)
[a, b]
BE 143 2.10 (0.00–4.45)
[a, g]
0 -
-
135 28.15 (20.56–35.73)
[a, d]
155 9.68 (5.02–14.33)
[a]
154 35.06 (27.53–42.60)
[a, b]
125d 4.80d (1.05-8.55)
-
57.60d (48.94–66.26)
-
DK 31 0
[a, d]
31 0
[a, b]
31 0
[e, f]
31 0
[a, b]
31 6.45 (0.00–15.10)
[c]
31 0
[a, b]
93.55 (44.41–84.90)
[c]
FR 215 7.44 (3.93–10.95)
[b, d]
211 6.64 (3.28-9.99)
[a]
212 17,92 (12.76-23.09)
[b, g]
214 9.81 (5.83-13.80)
[a]
216 27.78 (21.80-33.75)
[a]
204 10.29 (6.12-14.46)
[a]
66.67 (60.20-73.14)
[a]
DE 10 0
[a, b, f]
10 10.00 (0.00–28.59)
[a, b, c]
10 50.00 (19.01–80.99)
[a, d]
10 0
[a, b, c]
10 20.00 (0.00–44.79)
[a, c, d]
10 0
[a, b]
50.00 (19.01–80.99)
[a, d]
EL 8 1R/7S
-
0 -
-
8 4R/4S
-
0 -
-
7 4R/3R
-
0 -
-
-
-
IT 12 0
[a, b, c]
12 8.33 (0.00–23.97)
[a, b, c]
12 41.67 (13.77–69.56)
[a, d, g]
12 8.33 (0.00–23.97)
[a, b, c]
12 66.67 (39.99–93.34)
[b, e]
12 8.33 (0.00–23.97)
[a, b, c]
16.67 (0.00–37.75)
[d]
NL 261 6.13 (3.22–9.04)
[a, b, e]
244 2.87 (0.77–4.96)
[a]
260 8.85 (5.39–12.30)
[c, e, h]
17 11.76 (0.00–27.08)
[a, c]
260 27.31 (21.89–32.72)
[a]
243d 3.29d (1.05–5.54)
-
69.96d (64.19–75.72)
-
PT 14 50.00 (23.81–76.19)
[e]
15 33.33 (9.48–57.19)
[c, d]
15 40.00 (15.21–64.79)
[a, g, i]
15 33.33 (9.48–57.19)
[c]
15 46.67 (21.42–71.91)
[a, e]
14 42.86 (16.93–68.78)
[c]
35.71 (10.61–60.81)
[b, d, e]
RS 1 0R/1S
-
1 1R/0S
-
1 0R/1S
-
1 0R/1S
-
0 -
-
0 -
-
-
-
ES 15 26.67 (4.29–49.05)
[c, e, f]
13 15.38 (0.00–35.00)
[a, d]
15 53.33 (28.09–78.58)
[d, i]
9 2R/7S
-
15 53.33 (28.09–78.58)
[b, d, e]
7 2MDR
-
4Full-S
-
SE 170 2.35 (0.07–4.63)
[a, f, g]
169 0
[b, e]
170 0.59 (0.00–1.74)
[f]
170 0.59 (0.00–1.74)
[b]
170 7.06 (3.21–10.91)
[c]
169 0
[b]
91.12 (86.84–95.41)
[c]
CH 17 0
[a, b, f]
17 0
[a, e]
17 23.53 (3.37–43.69)
[a, g, h, I, j]
17 5.88 (0.00–17.07)
[a, b, c]
17 35.29 (12.58–58.01)
[a, e]
17 0
[a, b]
64.71 (41.99–87.42)
[a, e]
UK 16 12.50 (0.00–28.70)
[a, b, f]
16 0
[a, e]
16 0
[b, e, f, j]
11 0
[a, b, c]
15 33.33 (9.48–57.19)
[a, e]
10 0
[a, b]
70.00 (41.60–98.40)
[a, c, e]
  1. AMC amoxicillin clavulanate, 3GC third generation cephalosporins, FLU fluoroquinolones, CN gentamicin, SXT trimethoprim/sulfamethoxazole, MDR multidrug-resistant, FullS fully-susceptible
  2. aCountries: AT, Austria; BE, Belgium; DK, Denmark; FR, France; DE, Germany; EL, Greece; IT, Italy; NL, the Netherlands; PT, Portugal; RS, Serbia; ES, Spain; SE, Sweden; CH, Switzerland; UK, United Kingdom.
  3. b95 % CI, 95 % Confidence interval.
  4. cStat. Dif., Statistical significant differences. Countries with no statistical difference are marked with the same letter. Countries were compared by Fisher exact test with an alpha value of 0.05. Countries with less than ten tested isolates were not compared. Regarding MDR and FullS, only countries tested for all the considered antimicrobials were compared
  5. n, Total number of Proteus spp. tested for the considered antimicrobial category
  6. dMDR and FullS percentages do not include resistance to 3GC for Belgium and resistance to CN for the Netherlands